Previous 10 | Next 10 |
2024-05-14 08:02:08 ET More on Ocugen Ocugen: Two Gene Therapy Data Readouts In 2024 To Drive Value Ocugen: A Speculative Buy In Biotech Growing Clinical Trials To Billion-Dollar Revenues Ocugen Q1 2024 Earnings Preview Ocugen stock jumps after $175M securiti...
All three first-in-class modifier gene therapy product candidates currently in the clinic with OCU400 Phase 3 in progress OCU400 on track to meet 2026 Biologics License Application (BLA) and Market Authorization Application (MAA) approval targets MALVERN, Pa., May 14, 2024 (GLOBE ...
2024-05-13 12:08:33 ET More on Ocugen Ocugen: Two Gene Therapy Data Readouts In 2024 To Drive Value Ocugen: A Speculative Buy In Biotech Growing Clinical Trials To Billion-Dollar Revenues Ocugen stock jumps after $175M securities filing Ocugen says EU backs a...
MALVERN, Pa., May 10, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, today announced that its Board of Directors declared a dividend of one on...
MALVERN, Pa., May 10, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, today announced that Dr. Shankar Musunuri...
2024-05-07 09:51:20 ET Ocugen (NASDAQ: OCGN) stock price has launched higher since last year, helped by the rising hopes that OCU400 will be approved by the Food and Drug Administration (FDA). The stock surged by over 378% from its lowest point in September and by 183% this year. OC...
MALVERN, Pa., May 03, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, today announced that it will host a conference call and live webcast to d...
Commercial National Financial Corp. (CNAF) is expected to report for Q1 2024 First National Bank Alaska (FBAK) is expected to report for Q1 2024 Cyxtera Technologies Inc. (CYXTQ) is expected to report for quarter end 2024-03-31 Brookfield Renewable Corporation Class A Subordinate (BEP...
MALVERN, Pa., May 02, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, today announced that Arun Upadhyay, PhD, Chief Scientific Officer, Head o...
2024-04-29 08:30:00 ET Since the start of the year, Ocugen (NASDAQ: OCGN) has been on fire. The biotech's shares have gained an eye-popping 122%, far surpassing the performance of small-cap growth stocks this year. (See the following graph.) What's fueling this rally? Is Ocugen's st...
News, Short Squeeze, Breakout and More Instantly...
• Established Medium Dose as Safe and Tolerable Dose in Current OCU410ST Clinical Trial • DSMB Determination to Proceed with High Dose Cohort Dosing MALVERN, Pa., June 21, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a bi...
MALVERN, Pa., June 20, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, today announced that the first patient h...